Skip to main content
Premium Trial:

Request an Annual Quote

People in the News

Genetic Technologies: Mark Ziirsen

Genetic Technologies has appointed Mark Ziirsen its CFO and company secretary. He has more than 25 years of experience in the life sciences, technology, and consumer segments, including leadership roles in finance with companies listed on the Australian Stock Exchange, such as Cochlear, Aristocrat Leisure, Coca-Cola Amatil, and Goodman Fielder. Ziirsen also founded CFO advisory firm Mark Ziirsen Advisory, according to his LinkedIn profile.

Diadem: Michael Rasche, Paul Kinnon

Diadem said it has named Michael Rasche CEO and member of its board of directors. Former CEO Paul Kinnon will continue to serve on the company's board and has been named chairman of Diadem US.

Rasche was previously chief commercial officer at miDiagnostics. Before that he was president and general manager of international business at Metabolon. He also held leadership positions at Definiens, Ayoxxa, Dako, Roche, and Bayer Diagnostics.

Trinity Biotech: Louise Tallon

Trinity Biotech has appointed Louise Tallon chief financial officer, starting in August. She will replace Des Fitzgerald, who has been Trinity's interim CFO since December 2023. Tallon is currently head of group finance at Inizio, a commercialization partner in the pharmaceuticals space. Before that, she was at UDG Healthcare for 16 years, where she held various senior finance roles.

The Dublin-based firm diagnostics and diabetes management firm also said that Simon Dunne, will leave the firm as chief accounting officer in August with his role being assumed by Tallon.

Sysmex America: Dan Zortman

Dan Zortman has been named the CEO of Sysmex America. He replaces Andy Hay who has been the CEO since 2021 and will remain Sysmex America's chairman and president. Zortman has more than 33 years of experience in the diagnostics industry and was most recently VP of commercial operation at Roche. Previously, he was national director of sales and marketing for Roche Canada. Before Roche, he worked in sales at Pharmacia Dx, Sanofi Diagnostics, now part of Beckman Coulter, Bio-Rad Laboratories, and Chiron, now part of Siemens.

Medix Biochemica: Lonnie Shoff

Medix Biochemica has appointed Lonnie Shoff to its board of directors. Shoff previously was president of the clinical diagnostics division at Thermo Fisher Scientific and was CEO of the global animal health and strategic portfolio group at Henry Schein, where she was also president of the global healthcare specialty group. She also held senior roles at Roche, including general manager and regional head.

Based in Espoo, Finland, Medix Biochemica supplies raw materials to the in vitro diagnostics industry, including antibodies and antigens.

ADLM: Paul Jannetto, Mark Cervinski, Janice Dickerson

The Association for Diagnostics & Laboratory Medicine, formerly the American Association for Clinical Chemistry, has elected Paul Jannetto as president-elect of its board. His term starts in August for one year, after which he will serve as ADLM's president from August 2025 to July 2026, followed by one year as its past president from August 2026 to July 2027. Jannetto is a professor in the department of laboratory medicine and pathology and a consultant at the Mayo Clinic. He also is the co-director in the clinical mass spectrometry lab, clinical and forensic toxicology lab, and the metals lab, and is the VP of supply chain management for the department of lab medicine and pathology.

ADLM also elected two new directors to the board. Mark Cervinski is the medical director of clinical chemistry and point-of-care testing at the Dartmouth Hitchcock Medical Center and serves as associate professor of pathology and laboratory medicine and director of the clinical chemistry fellowship program at the Geisel School of Medicine at Dartmouth College. Jane Dickerson is division head of laboratory medicine, director of the core lab, director of reference lab services, and the CLIA medical director at the North Clinic at Seattle Children's Hospital. She is also an associate professor at the University of Washington and a cofounder and director of clinical services for Patient-centered Laboratory Utilization Guidance Services, a national collaboration to improve test ordering, retrieval, interpretation, and reimbursement.

Agilent Technologies: Bret DiMarco

Agilent Technologies has appointed Bret DiMarco as senior VP, chief legal officer, and secretary, effective July 1. He most recently served as the chief legal officer of the software-as-a-service firm, where he led the sale and closing processes for the company's merger with the firm II-VI Incorporated and served as a special adviser to the company's president during the transition period. DiMarco previously was the executive VP, chief legal officer, and corporate secretary for laser manufacturer Coherent, and he also was an associate and member of the law firm Wilson Sonsini Goodrich & Rosati, where he focused on corporate and securities law, corporate governance, and mergers and acquisitions. He is the chair of the Nasdaq Exchange Nominating Committee, and has been an adjunct assistant professor of law at the University of California Law School, San Francisco since 2004. DiMarco is a graduate of the University of Southern California Law School and received his bachelor’s degree from UC Irvine.

CND Life Sciences: Hernan Lopez, Kathryn Van Wie, Annemarie Benton, Bryan May

Neurodegenerative disease diagnostic firm CND Life Sciences this week said Hernan Lopez has joined the company as chief operating officer, while Kathryn Van Wie has been appointed VP of strategy and business development, Annemarie Benton was named VP of market access, and Bryan May was named VP of information technology.

Lopez has almost 20 years of experience with medical device and life science companies, and prior to joining CND, he was EVP of operations at GT Medical Technology. Meanwhile, Van Wie is an attorney who spent a decade at Vertex Pharmaceuticals as corporate counsel, then subsequently in US marketing and as chief of staff in commercial strategy and operations.

Benton was head of managed care at Bionano Genomics before moving to CND, and May was at Atara Biotherapeutics where he supported infrastructure and cloud services.

Danaher: Julie Sawyer Montgomery, Joakim Weidemanis

Danaher has appointed Julie Sawyer Montgomery to succeed Joakim Weidemanis as executive vice president of diagnostics, effective July 1. Weidemanis will support the transition and retire from Danaher on Sept. 30. 

Sawyer Montgomery is currently the VP and group executive of Danaher's clinical diagnostics businesses. She previously served as president of Danaher subsidiary Beckman Coulter Diagnostics and held leadership roles at Hospira Infusion Systems, Boston Scientific, and Boston Consulting Group.

Weidemanis joined Danaher in 2011 and previously oversaw the firm's product identification and water quality businesses.

Oncocyte: Andrea James

Oncocyte has appointed Andrea James as CFO. James most recently served as chief communications officer and head of investor relations at Axon Enterprise. She also worked in a strategic investor relations role for Tesla from 2016 to 2017. Prior to that, James was a sell-side analyst for Dougherty & Company (now Colliers Securities), eventually becoming a VP and senior research analyst. She has also been a business and financial reporter at various news publications including Bloomberg News and the Seattle Post-Intelligencer. James holds a bachelor's degree in computer information systems from American University and a master's degree in journalism from Northwestern University.